Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Product (Vaccines, Antiviral Drugs, Chemotherapy, Targeted Therapy, Immunosuppressants, Corticosteroids, Others), By Disease (Hepatitis, Non-alcoholic Fatty Liver Disease (NAFLD), Hepatic Cancer, Genetic Disorders, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Liver Disease Therapeutics Market Size & Growth Analysis

The global liver disease therapeutics market size was valued at USD 21.74 billion in 2025 and is projected to grow from USD 23.41 billion in 2026 to USD 42.28 billion by 2034, registering a CAGR of 7.67% during the forecast period from 2026 to 2034. North America dominated the liver disease therapeutics market with a market share of 38.92% in 2025.

The global liver disease therapeutics market encompasses a diverse range of treatment modalities, including vaccines, antiviral drugs, chemotherapy, targeted therapies, immunosuppressants, corticosteroids, and other supportive treatments. These therapeutics are utilized across multiple liver disease indications such as hepatitis, non-alcoholic fatty liver disease, hepatic cancer, genetic liver disorders, and related conditions, addressing both disease management and progression prevention across varied clinical settings.

Product Insights

The antiviral drugs segment dominated the market in 2025, accounting for 36.74% revenue share. This growth is driven by the increasing clinical preference for genotypic antiviral regimens that eliminate the necessity for genotype testing, notably reducing diagnostic complexity, treatment initiation time, and healthcare system burden, especially in high-volume public treatment programs.

The targeted therapy segment is estimated to register the fastest CAGR of 8.71% during the forecast period, owing to the rising development of liver-selective molecular therapies engineered to minimize systemic exposure, enabling higher dosing precision and improved safety profiles, which is driving faster clinical adoption across chronic and progressive liver disease indications.

Request Customizationto receive a tailored report.

Disease Insights

The hepatitis segment dominated the market with the highest revenue share of 41.03% in 2025. This growth is attributed to the high recurrence of treatment-experienced hepatitis patients requiring retreatment with antivirals, creating sustained demand within the hepatitis disease segment beyond first-line therapy initiation.

The non-alcoholic fatty liver disease (NAFLD) segment is projected to register the fastest CAGR of 8.76% from 2026-2034, due to rising focus on therapies targeting hepatic lipid metabolism and insulin resistance, which directly address the underlying pathophysiology of NAFLD, driving increased adoption of novel pharmacological interventions in this patient population.

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America dominated the liver disease therapeutics market in 2025, accounting for 38.92% market share. This growth is augmented by its established public health programs for hepatitis screening and treatment in the U.S., which facilitate early diagnosis and timely therapy initiation. This proactive approach increases patient access to antivirals and advanced liver therapies, driving sustained regional market expansion.

Canada market growth is driven by the wide public and private reimbursement of GIVLAARI (givosiran), an RNA interference therapy for acute hepatic porphyria, ensuring funded access nationwide. This broad coverage for an ultra-rare liver condition enhances uptake of advanced liver therapeutics and signals expanding payer support for innovative treatment modalities in the Canadian market.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Market Insights

Asia Pacific is emerging as the fastest-growing region with a CAGR of 9.83% from 2026 to 2034, owing to the expansion of government‑backed hepatitis treatment financing and universal access programs, where multiple countries now include HBV and HCV therapies under national insurance or public funding schemes. This reduces out‑of‑pocket costs, increases treatment uptake, and strengthens therapeutic demand across large patient populations.

Australia's liver disease therapeutics market growth is supported by the inclusion of new chronic liver medicines like Iqirvo (elafibranor) on the Pharmaceutical Benefits Scheme (PBS), markedly reducing patient costs to under AUD 40 per prescription. This government subsidy dramatically improves therapy affordability and accessibility, driving higher treatment uptake across chronic liver disease populations nationwide.

Europe Market Insights

Europe's liver disease therapeutics market is boosted by the region’s conditional authorisation mechanism to expedite access to innovative liver therapies, such as the conditional approval recommendation for Rezdiffra for NASH/MASH. This regulatory flexibility allows earlier market availability of breakthrough treatments, encouraging clinician adoption and investment in advanced liver therapeutics across the region.

In Germany, the market is experiencing notable growth, driven by a high concentration of advanced clinical trial activity and hepatology expertise within leading university hospitals, especially in Berlin, Munich, and Heidelberg. This robust research ecosystem accelerates early adoption of innovative therapies and supports evidence-based treatment protocols across complex liver conditions.

Latin America Market Insights

Latin America’s liver disease therapeutics market is being driven by the wider availability of generic direct-acting antiviral (DAA) formulations through regional procurement agreements and government programs, which have reduced treatment costs and expanded access across Brazil, Mexico, and Argentina, facilitating broader therapy adoption in underserved populations.

The growth of Argentina's market is driven by the government’s long-standing policy of incorporating direct‑acting antiviral (DAA) treatments for hepatitis B and C into the public health system free of charge, expanding access regardless of fibrosis stage, and improving treatment penetration nationwide.

Middle East and Africa Market Insights

The Middle East and Africa liver disease therapeutics market growth is stimulated by the region’s exceptionally high prevalence of non‑alcoholic fatty liver disease, particularly in Gulf states, driven by rapid lifestyle changes and metabolic risk factors. This elevated disease burden increases clinical demand for advanced liver therapies and accelerates market uptake across the region.

South Africa market growth is supported by the accelerating adoption of non-invasive screening for NAFLD and NASH, integrated into routine diabetes and obesity care pathways. This increased early detection has expanded identification of at‑risk patients eligible for therapeutic intervention, boosting demand for pharmacological treatments in clinical practice.

Competitive Landscape

The global liver disease therapeutics market is moderately consolidated, with several multinational pharmaceutical and biotech companies leading key segments. Market leaders maintain their position through continuous R&D, strategic partnerships, and regulatory approvals. Prominent players include Gilead Sciences, AbbVie, Bristol-Myers Squibb, Roche, Merck, Intercept Pharmaceuticals, Alnylam Pharmaceuticals, and others, focusing on innovative antivirals, targeted therapies, and RNA-based treatments to address chronic liver conditions worldwide.

Tune Therapeutics: An Emerging Market Player

Tune Therapeutics is an emerging biotech company developing a novel epigenetic gene tuning therapy for chronic hepatitis B, aiming to disable viral replication in liver cells with a single injectable treatment.

• In early 2025, it raised $175 million to advance clinical trials across multiple regions, highlighting its potential to transform treatment for persistent viral liver infections and address unmet therapeutic demand in the market.

List of Key and Emerging Players in Liver Disease Therapeutics Market